Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to...
July 16 2018 - 4:05PM
Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today
announced the closing of its previously announced underwritten
public offering of 4,600,000 shares of its common stock to the
public at $36.00 per share, which included the exercise in full by
the underwriters of their option to purchase 600,000 additional
shares of common stock. The gross proceeds to Assembly from this
offering were $165.6 million, before deducting underwriting
discounts and commissions and other estimated offering expenses
payable by Assembly. Assembly intends to use the net proceeds from
the sale of the common stock to fund clinical trials, nonclinical
studies, research and development and for general corporate
purposes.
Jefferies LLC, Leerink Partners LLC, William Blair &
Company, L.L.C. and Mizuho Securities USA LLC acted as joint
bookrunning managers for the offering. Robert W. Baird & Co.
Incorporated acted as lead manager, and National Securities
Corporation acted as co-manager for the offering.
The securities described above were offered pursuant to two
shelf registration statements (File Nos. 333-208806 and
333-222366), which were declared effective by the United States
Securities and Exchange Commission (“SEC”) on January 19, 2016 and
January 10, 2018, respectively. A final prospectus supplement
relating to this offering was filed with the SEC on June 13, 2018
and is available on the SEC’s website at www.sec.gov. Copies of the
final prospectus supplement and accompanying prospectuses may be
obtained by contacting Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at prospectus
department@jefferies.com; Leerink Partners LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@leerink.com; William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, by telephone at (800) 621-0687, or by email at
prospectus@williamblair.com; or Mizuho Securities USA LLC,
Attention: Equity Capital Markets, 320 Park Ave., New York, NY
10022, or by email at US-ECM@us.mizuho-sc.com, or by telephone at
(212) 205-7600.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public
biotechnology company developing two innovative platform programs:
an HBV program advancing a new class of oral therapeutic candidates
for the treatment of hepatitis B virus (HBV) infection and a
microbiome program developing novel oral synthetic live
biotherapeutic candidates for disorders associated with the
microbiome. Assembly’s HBV-cure program is advancing multiple drug
candidates with the aim of increasing cure rates in patients with
chronic HBV. Assembly’s microbiome program consists of a fully
integrated platform that includes a robust strain identification
and selection process, methods for strain isolation and growth
under current Good Manufacturing Practices and a patented delivery
system, GEMICEL®, which allows for targeted oral delivery of live
biologic and conventional therapies to the lower gastrointestinal
tract.
Forward-Looking Statements
The information in this press release contains forward-looking
statements regarding future events, including statements about
Assembly’s use of proceeds. Assembly intends such forward-looking
statements to be covered by the safe harbor provisions contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. More
information about the risks and uncertainties faced by Assembly are
more fully detailed under the heading “Risk Factors” in Assembly’s
Annual Report on Form 10-K for the year ended December 31, 2017,
and its Quarterly Report on Form 10-Q for the quarter ended March
31, 2018 filed with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking
statements, which apply only as of the date of this press release.
Except as required by law, Assembly assumes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts
Investors: Lauren Glaser (415) 521-3828
lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024